Drug intelligence / Profile preview

tanespimycin + trastuzumab

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

Tanespimycin + trastuzumab is a combination therapy consisting of tanespimycin (17-AAG, KOS-953), a heat shock protein 90 (HSP90) inhibitor, and trastuzumab (Herceptin), a monoclonal antibody targeting HER2. This combination was developed for HER2-positive metastatic breast cancer patients whose disease progressed during prior trastuzumab treatment. Tanespimycin inhibits HSP90, leading to degradation of client proteins including HER2, potentially resensitizing trastuzumab-resistant tumors to trastuzumab therapy.

Targets

HSP90 (Heat shock protein 90 chaperone complex)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on tanespimycin + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tanespimycin + trastuzumab.

Explore the full profile